MRNA

MARINA BIOTECH INC COM STK (DE)
MRNA

Delisted

MRNA was delisted on the 22nd of December, 2011.

Back to rankings

Healthcare Drug Manufacturers - General

Financial journalist opinion

US cancels more $700 million funding for Moderna bird flu vaccine

The Trump administration has cancelled a contract awarded to Moderna for the late-stage development of its bird flu vaccine for humans, as well as the right to purchase shots, according to the drugmaker.

US cancels more $700 million funding for Moderna bird flu vaccine

Moderna Announces Update on Investigational Pandemic Influenza Program

Phase 1/2 H5 avian flu vaccine study shows positive interim results Company has been notified that HHS will terminate Moderna's award for late-stage development of pre-pandemic influenza vaccines CAMBRIDGE, MA / ACCESS Newswire / May 28, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced positive interim data from a Phase 1/2 clinical study (NCT05972174) evaluating the safety and immunogenicity of its investigational pandemic influenza vaccine, mRNA-1018, in approximately 300 healthy adults aged 18 years and older. The interim results focus on a vaccine candidate targeting the H5 avian influenza virus subtype.

Moderna Announces Update on Investigational Pandemic Influenza Program

Schaeffers Research

Cautious? Risky? Our Volatility Scorecard Can Help

Our volatility scorecard has a pretty good feel for the market right now.

Cautious? Risky? Our Volatility Scorecard Can Help

Moderna to Present at Upcoming Conferences in June 2025

CAMBRIDGE, MA / ACCESS Newswire / May 27, 2025 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conferences: Jefferies Global Health Care Conference, on Thursday, June 5th at 10:30am ET Goldman Sachs 46th Annual Global Healthcare Conference, on Wednesday, June 11th at 8:40am ET A live webcast of each of these presentations will be available under "Events and Presentations" in the Investors section of the Moderna website. investors.modernatx.com.

Moderna to Present at Upcoming Conferences in June 2025

Zacks Investment Research

MRNA Seeks FDA Nod for Updated COVID-19 Vaccine

Moderna files with FDA for updated Spikevax aimed at the LP.8.1 variant, which makes up 70% of U.S. COVID-19 cases.

MRNA Seeks FDA Nod for Updated COVID-19 Vaccine

Will Moderna's Rally Continue?

Moderna (NASDAQ: MRNA) has caught the market off guard with a significant recovery in recent days – reaching current levels of approximately $27 after hitting a five-year low of $23.15 last week – following the FDA's decision to continue advising annual COVID-19 vaccinations for high-risk populations. However, this abrupt rally appears to be a singular occurrence – competitors such as Pfizer (NYSE: PFE), Sarepta Therapeutics (NASDAQ: SRPT), and CureVac (NASDAQ:CVAC) did not replicate Moderna's increase – implying the rise was primarily fueled by the FDA guidance rather than a wider sector uptrend.

Will Moderna's Rally Continue?

Moderna files application for updated COVID vaccine

Moderna said on Friday it had filed a marketing application for an updated COVID vaccine to the U.S. Food and Drug Administration.

Moderna files application for updated COVID vaccine

Moderna Files FDA Application for the LP.8.1 Targeting COVID-19 Vaccine

CAMBRIDGE, MA / ACCESS Newswire / May 23, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that it has submitted an application to the U.S. Food and Drug Administration (FDA) for review of its Spikevax 2025-2026 formula, targeting the SARS-CoV-2 variant LP.8.1. The submission is based on guidance from the U.S. FDA, which advised that COVID-19 vaccines should be updated to a monovalent JN.1 lineage, with a preference for the LP.8.1 variant.

Moderna Files FDA Application for the LP.8.1 Targeting COVID-19 Vaccine

Zacks Investment Research

MRNA Stock Down on Withdrawal of FDA Filing for COVID-Flu Combo Shot

Moderna's voluntary withdrawal of the filing stems from the FDA's request for vaccine efficacy data from a phase III study on the experimental flu shot.

MRNA Stock Down on Withdrawal of FDA Filing for COVID-Flu Combo Shot

Moderna Stock Looks Ripe for a Short Squeeze

Moderna Inc. NASDAQ: MRNA is down 35% in 2025, making it one of the worst-performing stocks among medical stocks and the broader market. Not surprisingly, the stock is down over 80% in the last 12 months.

Moderna Stock Looks Ripe for a Short Squeeze

See News Rankings

Charts implemented using Lightweight Charts™